S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
S&P 500   3,950.63 (+0.87%)
DOW   32,235.84 (+1.17%)
QQQ   305.12 (-0.08%)
AAPL   157.47 (+1.59%)
MSFT   270.61 (-3.16%)
META   197.74 (+1.09%)
GOOGL   101.17 (-0.44%)
AMZN   97.32 (-1.65%)
TSLA   183.33 (+1.78%)
NVDA   258.28 (+0.40%)
NIO   8.69 (+5.21%)
BABA   80.89 (-0.96%)
AMD   96.03 (-1.85%)
T   18.49 (+1.99%)
F   11.23 (-0.62%)
MU   57.36 (+1.24%)
CGC   1.87 (-6.50%)
GE   89.81 (-0.53%)
DIS   94.02 (+0.88%)
AMC   4.33 (+3.59%)
PFE   40.75 (+1.62%)
PYPL   73.02 (+0.04%)
NFLX   304.65 (+0.38%)
NASDAQ:CALA

Calithera Biosciences - CALA Price Target & Analyst Ratings

$0.05
0.00 (0.00%)
(As of 03/20/2023 03:22 PM ET)
Add
Compare
Today's Range
$0.04
$0.05
50-Day Range
$0.05
$0.66
52-Week Range
$0.04
$13.38
Volume
70,861 shs
Average Volume
359,678 shs
Market Capitalization
$243,500.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

Calithera Biosciences Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 3 Analyst Ratings

Consensus Analyst Price Target

$18.67
37,233.33% Upside
High Prediction$30.00
Average Prediction$18.67
Low Prediction$8.00
TypeCurrent
3/20/22 to 3/20/23
1 Month Ago
2/18/22 to 2/18/23
3 Months Ago
12/20/21 to 12/20/22
1 Year Ago
3/20/21 to 3/20/22
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.67$18.67$18.67$73.33
Predicted Upside37,233.33% Upside413.88% Upside413.88% Upside354.56% Upside
Get Calithera Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CALA and its competitors with MarketBeat's FREE daily newsletter.

CALA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CALA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Calithera Biosciences Stock vs. The Competition

TypeCalithera BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.64
2.47
Consensus RatingHoldBuyHold
Predicted Upside37,233.33% Upside3,856.53% Upside24.74% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/15/2022LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/15/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
8/29/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Ramakanth
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$8.00+144.65%
11/5/2021William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Phipps
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
1/5/2021Smith Barney Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$200.00 ➝ $100.00+90.84%
5/11/2020Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$140.00 ➝ $200.00+50.38%
3/27/2020Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$120.00+34.23%
(Data available from 3/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












CALA Price Target - Frequently Asked Questions

What is Calithera Biosciences's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Calithera Biosciences stock is Hold based on the current 2 hold ratings and 1 buy rating for CALA. The average twelve-month price prediction for Calithera Biosciences is $18.67 with a high price target of $30.00 and a low price target of $8.00. Learn more on CALA's analyst rating history.

Do Wall Street analysts like Calithera Biosciences more than its competitors?

Analysts like Calithera Biosciences less than other Medical companies. The consensus rating for Calithera Biosciences is Hold while the average consensus rating for medical companies is Buy. Learn more on how CALA compares to other companies.

Does Calithera Biosciences's stock price have much upside?

According to analysts, Calithera Biosciences's stock has a predicted upside of 413.88% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:CALA) was last updated on 3/20/2023 by MarketBeat.com Staff